Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations

Area of Science:

• Gerontology
• Pharmacology
• Cardiology

Background:

• The aging population is increasing globally, leading to more elderly patients using cardiovascular drugs.
• Cardiovascular drug use is expanding for primary and early secondary prevention in older adults, even without significant organ impairment.
• Traditional considerations for elderly patients focused on advanced organ disease; current use includes those with less severe conditions.

Purpose of the Study:

• To systematically review the effects of aging on pharmacokinetic and pharmacodynamic properties of cardiovascular drugs.
• To assess age-related changes in drug handling and response in the absence of major co-morbidities.
• To identify gaps in knowledge regarding cardiovascular drug use in the elderly, particularly those over 80.

Main Methods:

• Systematic review of existing literature.
• Focus on studies examining aging effects on cardiovascular drug pharmacokinetics and pharmacodynamics.
• Inclusion of studies on both traditional and newer cardiovascular medications.

Main Results:

• Evidence on age-related pharmacokinetic and pharmacodynamic effects is often poor or non-existent for many cardiovascular drugs.
• Existing studies are frequently small and underpowered, limiting reliable data interpretation.
• There is a significant lack of information regarding drug use in individuals over 80 years of age.

Conclusions:

• Current evidence is insufficient to guide the optimal use of cardiovascular drugs in the aging population.
• Further well-designed studies are crucial to understand age-specific effects and ensure safe and effective prescribing.
• Special attention is needed for the rapidly growing population of very elderly patients (>80 years).